Oxidative signaling is a central mechanism in alcohol-induced injury and has a strong implication in blood-brain barrier (BBB) dysregulation and neuroinflammation. Here, by targeting oxidative signaling, we hypothesized an innovative approach to develop a clinically relevant therapeutic strategy for alleviating alcohol-mediated neurovascular damage. To accomplish this, we enhanced the endogenous activity of Nrf2 (nuclear factor E2-related factor 2) by treating with an Nrf2 activator III TAT peptide (Nrf2 peptide, NP) and investigated the neuroprotective role of Nrf2 in promoting antioxidant defense properties and reducing BBB damage and transmigration of leukocytes to the brain following alcohol ingestion. We administered the NP subcutaneously to alcohol-ingested mice and evaluated its therapeutic potential in alleviating alcohol-associated neurovascular impairments. We compared the results with control peptide (random sequence with TAT)-treated animals. The studies showed that the NP treatment preserved the oxidant-antioxidant balance, downregulated ICAM-1 and its receptors, and mitigated BBB damage and leukocyte infiltration into the brain. We validated the effect of the NP in Nrf2 knock-out (KO) mice ( Nrf2 −/− ). Thus, this study demonstrates NP’s neurovascular protective effects by regulating the oxidant-antioxidant balance, reducing oxidative stress-induced BBB disruption, and limiting transmigration of immune cells to the brain in a mouse model of alcohol ingestion.
Saikia et al. (Tue,) studied this question.